Drug
QL1206 clinical trials
Also written QL1206.
A product of Denosumab; its studies count on that page too.
- studies test it
- 5
- open now
- 1
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the QL1206 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses QL1206 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®RecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07062978Written as QL1206
- To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid TumorsStatus unknownPhase 3Qilu Pharmaceutical Co., Ltd.NCT04550949Written as QL1206
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy AdultsStatus unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT04213105Written as QL1206
- Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture RiskStatus unknownPhase 3Qilu Pharmaceutical Co., Ltd.NCT04128163Written as QL1206
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsCompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT03651947Written as QL1206